{
 "page": "https://www.cemmeydan.com/evidence/",
 "markdown": "https://www.cemmeydan.com/evidence.md",
 "lastReviewed": "2026-10-31",
 "studyGroups": [
  {
   "id": "chromatin",
   "title": "Chromatin remodeling and lymphoma",
   "dates": "Nature, 2026 · Cancer Cell, 2024",
   "preview": "Studies of BAF disruption connected chromatin remodeling with altered CTCF binding, 3D genome organization, and lymphoma cell identity. Dr. Meydan led computational analyses and supervised contributing researchers in the 2026 Nature study. He shares first and corresponding authorship on that paper. He also shares first authorship on the 2024 ARID1A study and is a named inventor on its related patent application.",
   "narrative": [
    "Two linked studies examined the SWI/SNF (BAF) chromatin-remodeling complex. The 2024 Cancer Cell study showed how ARID1A loss reprograms B cells and exposes a therapeutic vulnerability in lymphoma. The 2026 Nature study showed how BAF disruption rewires CTCF binding and 3D genome organization across cancers.",
    "Dr. Meydan led the computational analyses and data curation of the 2026 study and supervised its computational and statistical work. He shares first and corresponding authorship on that paper. On the 2024 study he shares first authorship and is credited with formal analysis and investigation. He is a named co-inventor on the international patent application that followed from the 2024 study."
   ],
   "studies": [
    "baf-ctcf",
    "arid1a"
   ],
   "relatedPapers": [],
   "sources": [],
   "url": "https://www.cemmeydan.com/evidence/#chromatin"
  },
  {
   "id": "spaceflight",
   "title": "An integrated view of human spaceflight",
   "dates": "Science, 2019 · Cell, 2020 · Nature, 2024",
   "preview": "The NASA Twins Study provided the first integrated biomolecular view of the human response to spaceflight. Subsequent work identified mitochondrial stress as a central response and helped establish SOMA’s shared atlas and astronaut biobank. Dr. Meydan shares first authorship on the Twins and mitochondrial-stress studies and corresponding authorship on SOMA. His contributions span integrative analysis, methods, and research resources.",
   "narrative": [
    "The NASA Twins Study combined molecular, physiological, and cognitive measurements before, during, and after a year-long spaceflight. An identical twin on Earth provided a genetically matched comparison. NASA described it as the first integrated biomolecular view of the human response to spaceflight. Dr. Meydan shares first authorship and contributed transcriptomic and integrative-analysis methods.",
    "The 2020 Cell study integrated astronaut profiles with experimental-model data and identified mitochondrial stress as a central biological response to spaceflight. Dr. Meydan shares first authorship and analyzed its DNA methylation data.",
    "SOMA, the Space Omics and Medical Atlas (Nature, 2024), connected molecular and clinical measurements across missions and combined a shared research resource with an international astronaut biobank. Dr. Meydan shares corresponding authorship; his contributions include methodology, formal analysis, investigation, and visualization, and he supervised computational and statistical work. A companion study records that he co-led the Inspiration4 and Twins data acquisition and sharing.",
    "Together, the studies moved from integrated measurement of one mission, to a biological synthesis across astronauts and model organisms, to shared data infrastructure. The work spans longitudinal, single-cell, and multiomic measurements of immune changes, mitochondrial stress, and host–microbiome responses."
   ],
   "studies": [
    "nasa-twins",
    "spaceflight-mitochondria",
    "soma"
   ],
   "relatedPapers": [],
   "sources": [
    {
     "title": "NASA’s 2019 account of the Twins Study",
     "url": "https://www.nasa.gov/news-release/nasas-landmark-twins-study-reveals-resilience-of-human-body-in-space/"
    }
   ],
   "url": "https://www.cemmeydan.com/evidence/#spaceflight"
  },
  {
   "id": "enasidenib-mechanism",
   "title": "Targeted therapy in acute myeloid leukemia",
   "dates": "Preclinical studies, 2014–2017 · First IDH2 inhibitor approved, 2017",
   "preview": "Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow. In some patients, mutations in the IDH2 gene disturb DNA methylation and block blood-cell maturation. Preclinical studies showed that targeted inhibition of mutant IDH2 reversed these changes and restored differentiation in leukemia models. The work was cited in the clinical development of the IDH2 inhibitor enasidenib, approved by the FDA in 2017. Dr. Meydan contributed methods and epigenomic analysis and shares first authorship on the 2017 study.",
   "narrative": [
    "Acute myeloid leukemia (AML) is an aggressive cancer of the blood and bone marrow; some cases carry mutations in IDH2. Preclinical studies linked mutant IDH2 inhibition to reduced abnormal DNA methylation and restored differentiation in leukemia models. The first enasidenib clinical report cited the 2014 AG-221 findings of Shih, Shank, Meydan and colleagues. A clinical-mechanism study cited both the 2014 work and the 2017 Cancer Discovery paper.",
    "Dr. Meydan shares first authorship on the 2017 paper. He contributed methodology and the computational analysis and interpretation of the epigenomic data. The FDA approved enasidenib in August 2017. The documented connection is the preclinical mechanism and its citation in the original clinical-development literature."
   ],
   "studies": [
    "enasidenib"
   ],
   "relatedPapers": [],
   "sources": [],
   "url": "https://www.cemmeydan.com/evidence/#enasidenib-mechanism"
  },
  {
   "id": "public-health",
   "title": "COVID-19 in New York: testing, viral genomics and host response",
   "dates": "2020–2022 · Nature Medicine · Nature Communications · Nature · Cell Reports Medicine",
   "preview": "During New York’s first COVID-19 wave, this research combined rapid RT-LAMP testing, viral genome sequencing, host-response profiling of nasopharyngeal swabs, autopsy and spatial tissue studies, and analyses of electronic health records. The RT-LAMP validation contributed to Color’s FDA emergency authorization in May 2020, when fully at-home self-testing was not yet available in the United States. Dr. Meydan shares first authorship on the Nature Communications study and corresponding authorship on the Cell Reports Medicine study of tissue damage.",
   "narrative": [
    "New York’s first COVID-19 wave created an urgent need for testing and molecular information. Clinical laboratories faced backlogs and shortages of PCR reagents. Fully at-home self-testing was not yet available in the United States.",
    "Rapid PCR instruments could shorten laboratory turnaround, but they still required dedicated equipment. RT-LAMP offered a different route to expanding molecular testing. The amplification reaction ran at a constant temperature and produced a visible color change in about 30 minutes. It reduced the instrumentation needed for detection and offered an alternative to constrained PCR workflows.",
    "The study combined RT-LAMP testing with viral sequencing, host-response profiling, and spatial measurements. Clinical specimens from 669 patients were collected during the first months of New York’s outbreak. The work characterized viral lineages and host responses and provided molecular data for further research. Dr. Meydan shares first authorship. His contributions included assay validation and genetic and statistical analyses.",
    "The assay was developed through a collaboration involving Weill Cornell Medicine, Color, and New England Biolabs. The validation results contributed to the evidence supporting Color’s FDA emergency authorization in May 2020. The study was published in Nature Communications in March 2021.",
    "Subsequent studies examined multi-organ transcriptional disruption, loss of tissue identity, lung inflammation and repair, and molecular associations with severe outcomes. Together, these studies addressed urgent questions about detection, viral variation, and host injury during the pandemic."
   ],
   "studies": [
    "rt-lamp",
    "covid-tissue",
    "covid-host"
   ],
   "relatedPapers": [
    "10.1126/sciadv.abe5984",
    "10.1126/scitranslmed.abq1533"
   ],
   "sources": [
    {
     "title": "Cepheid emergency authorization announcement, March 21, 2020",
     "url": "https://cepheid.mediaroom.com/2020-03-21-Cepheid-Receives-Emergency-Use-Authorization-from-FDA-for-Rapid-SARS-CoV-2-Test"
    },
    {
     "title": "FDA: first fully at-home self-test, November 17, 2020",
     "url": "https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-first-covid-19-test-self-testing-home"
    },
    {
     "title": "FDA: first over-the-counter fully at-home test, December 15, 2020",
     "url": "https://www.fda.gov/news-events/press-announcements/coronavirus-covid-19-update-fda-authorizes-antigen-test-first-over-counter-fully-home-diagnostic"
    },
    {
     "title": "Weill Cornell’s early COVID-19 testing program",
     "url": "https://research.weill.cornell.edu/about-us/news-updates/covid-19-testing-program-built-ground-amid-escalating-pandemic"
    }
   ],
   "url": "https://www.cemmeydan.com/evidence/#public-health",
   "relatedTechnologyContext": {
    "heading": "Low-infrastructure diagnostic platforms",
    "text": "TINY, developed by the Erickson and Cesarman teams, illustrates the broader potential of isothermal diagnostics in resource-limited settings. Its thermal system can use sunlight, a flame, or electricity and store heat through power interruptions. Earlier field testing in Uganda concerned Kaposi sarcoma-associated herpesvirus. Mozsary and colleagues subsequently evaluated SARS-CoV-2 testing on the platform.",
    "sources": [
     {
      "title": "Snodgrass et al., Nature Biomedical Engineering, 2018",
      "url": "https://www.nature.com/articles/s41551-018-0286-y"
     },
     {
      "title": "Cornell Chronicle, September 11, 2018",
      "url": "https://news.cornell.edu/stories/2018/09/tiny-cancer-detection-device-proves-effective-uganda-testing"
     },
     {
      "title": "Mozsary et al., 2021 (PubMed Central)",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8802758/"
     },
     {
      "title": "PubMed record",
      "url": "https://pubmed.ncbi.nlm.nih.gov/35136383/"
     }
    ]
   }
  },
  {
   "id": "urban-microbiome",
   "title": "Urban microbiome mapping",
   "dates": "Cell Systems, 2015 · Cell, 2021",
   "preview": null,
   "narrative": [
    "PathoMap produced the first city-scale DNA map of a subway system, sampling all 466 open New York stations. It made the front page of The Wall Street Journal and led to the global MetaSUB consortium. Dr. Meydan shares first authorship on the 2015 Cell Systems study.",
    "The International MetaSUB Consortium’s global atlas of urban microbiomes and antimicrobial resistance covered 60 cities (Cell, 2021). The MetaSUB Map portal credits Cem Meydan and David Danko, and the StuckOnU 2017 page credits its website and visualizations to Dr. Meydan. This is earlier research; the lab’s current host–microbiome questions are part of its inflammation and metabolism research."
   ],
   "studies": [],
   "relatedPapers": [
    "10.1016/j.cels.2015.01.001",
    "10.1016/j.cell.2021.05.002"
   ],
   "sources": [],
   "url": "https://www.cemmeydan.com/evidence/#urban-microbiome"
  }
 ],
 "contributions": [
  {
   "id": "baf-ctcf",
   "title": "SWI/SNF, CTCF, and the 3D genome",
   "venue": "Nature",
   "year": "2026",
   "paperDoi": "10.1038/s41586-026-11197-w",
   "studyGroup": "chromatin",
   "personId": "https://www.cemmeydan.com/#cem-meydan",
   "personName": "Cem Meydan",
   "authorship": [
    "First author",
    "Corresponding author"
   ],
   "personRoles": [
    "co-first author",
    "co-corresponding author",
    "led computational analyses",
    "data curation",
    "supervision of computational and statistical work"
   ],
   "finding": "The study connected BAF disruption with altered CTCF binding, 3D genome organization, and cancer-associated gene regulation.",
   "contribution": "Led the computational analyses and data curation, and supervised the computational and statistical work.",
   "detail": [
    "Dr. Meydan’s contributions also included visualization and manuscript review. Sonia Debek, Cem Meydan, and Christopher Chin share first authorship. Ari Melnick, Darko Barisic, and Cem Meydan share corresponding authorship.",
    "Experimental therapeutic implications remain tied to the study’s model systems."
   ],
   "sources": [
    {
     "claim": "Finding and authorship",
     "title": "Debek, Meydan, Chin et al., Nature",
     "publisher": "Nature, 2026",
     "url": "https://www.nature.com/articles/s41586-026-11197-w",
     "locator": "Author contributions",
     "establishes": "The study’s findings and shared first and corresponding authorship. The contribution statement reads: “C. Meydan led the computational analyses and data curation.”"
    },
    {
     "claim": "Institutional summary",
     "title": "A unifying mechanism for cancer-driving mutations",
     "publisher": "Weill Cornell Medicine, October 2026",
     "url": "https://news.weill.cornell.edu/news/2026/10/a-unifying-mechanism-for-cancer-driving-mutations",
     "locator": "",
     "establishes": "Institutional account of the study."
    },
    {
     "claim": "Analysis code",
     "title": "Nature_2026_BAF_CTCF",
     "publisher": "GitHub (meydan-lab)",
     "url": "https://github.com/meydan-lab/Nature_2026_BAF_CTCF",
     "locator": "",
     "establishes": "Transcription-factor regulatory-potential and chromatin-model analysis code."
    },
    {
     "claim": "Processing code",
     "title": "multiome_process",
     "publisher": "GitHub (crchin)",
     "url": "https://github.com/crchin/multiome_process",
     "locator": "",
     "establishes": "Multiome processing code."
    },
    {
     "claim": "Data",
     "title": "GSE294051 and GSE237990",
     "publisher": "NCBI GEO",
     "url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294051",
     "locator": "",
     "establishes": "Accessions linked from the paper."
    }
   ],
   "evidenceScope": "The paper documents the findings, shared first and corresponding authorship, and that Dr. Meydan led the computational analyses and data curation.",
   "summaryUrl": "https://www.cemmeydan.com/#chromatin",
   "detailsUrl": "https://www.cemmeydan.com/evidence/#baf-ctcf",
   "lastReviewed": "2026-10-31",
   "resources": [
    {
     "type": "Code",
     "name": "Nature 2026 analysis code (meydan-lab)",
     "url": "https://github.com/meydan-lab/Nature_2026_BAF_CTCF"
    },
    {
     "type": "Code",
     "name": "Multiome processing code (crchin)",
     "url": "https://github.com/crchin/multiome_process"
    },
    {
     "type": "Public data",
     "name": "GEO GSE294051",
     "url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE294051"
    },
    {
     "type": "Public data",
     "name": "GEO GSE237990",
     "url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237990"
    }
   ]
  },
  {
   "id": "arid1a",
   "title": "ARID1A loss in lymphoma: mechanism and therapeutic vulnerability",
   "venue": "Cancer Cell",
   "year": "2024",
   "paperDoi": "10.1016/j.ccell.2024.02.010",
   "studyGroup": "chromatin",
   "personId": "https://www.cemmeydan.com/#cem-meydan",
   "personName": "Cem Meydan",
   "authorship": [
    "First author"
   ],
   "personRoles": [
    "co-first author",
    "formal analysis",
    "investigation"
   ],
   "finding": "The study linked ARID1A loss and altered B-cell fate to a vulnerability to SMARCA2/SMARCA4 inhibition. The work led to an international patent application for the use of these inhibitors in lymphoma.",
   "contribution": "Formal analysis and investigation; named co-inventor on the resulting patent application.",
   "detail": [
    "The international application WO 2025/096976 A1 was published on May 8, 2025. The published inventors are Darko Barisic, Ari Melnick, Christopher Chin, and Cem Meydan. The applicant is Cornell University."
   ],
   "sources": [
    {
     "claim": "Finding and authorship",
     "title": "Barisic, Chin, Meydan et al., Cancer Cell",
     "publisher": "Cancer Cell, 2024",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11407687/",
     "locator": "Author contributions",
     "establishes": "The study’s findings and listed contributions."
    },
    {
     "claim": "Inventorship and application",
     "title": "WO2025096976A1",
     "publisher": "WIPO, published May 8, 2025",
     "url": "https://patents.google.com/patent/WO2025096976A1/en",
     "locator": "Inventors",
     "establishes": "Named inventors and the published international application."
    },
    {
     "claim": "Analysis code",
     "title": "Barisic_et_al_CancerCell_2024",
     "publisher": "GitHub (melnick-lab)",
     "url": "https://github.com/melnick-lab/Barisic_et_al_CancerCell_2024",
     "locator": "",
     "establishes": "Study analysis code."
    },
    {
     "claim": "Data",
     "title": "GSE237990",
     "publisher": "NCBI GEO",
     "url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237990",
     "locator": "",
     "establishes": "Study data accession."
    }
   ],
   "evidenceScope": "The paper documents the findings and Dr. Meydan’s listed contributions. The patent record lists the named inventors and the published international application.",
   "summaryUrl": "https://www.cemmeydan.com/#chromatin",
   "detailsUrl": "https://www.cemmeydan.com/evidence/#arid1a",
   "lastReviewed": "2026-10-31",
   "invention": {
    "role": "named co-inventor",
    "application": "WO2025096976A1",
    "published": "2025-05-08",
    "url": "https://patents.google.com/patent/WO2025096976A1/en",
    "label": "International patent application"
   },
   "resources": [
    {
     "type": "Code",
     "name": "Study analysis code (melnick-lab)",
     "url": "https://github.com/melnick-lab/Barisic_et_al_CancerCell_2024"
    },
    {
     "type": "Public data",
     "name": "GEO GSE237990",
     "url": "https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE237990"
    }
   ]
  },
  {
   "id": "soma",
   "title": "SOMA: spaceflight data and research infrastructure",
   "venue": "Nature",
   "year": "2024",
   "paperDoi": "10.1038/s41586-024-07639-y",
   "studyGroup": "spaceflight",
   "personId": "https://www.cemmeydan.com/#cem-meydan",
   "personName": "Cem Meydan",
   "authorship": [
    "Corresponding author"
   ],
   "personRoles": [
    "co-corresponding author",
    "methodology",
    "formal analysis",
    "investigation",
    "visualization",
    "supervision of computational and statistical work",
    "co-led Inspiration4 data acquisition and sharing"
   ],
   "finding": "The Space Omics and Medical Atlas connects molecular and clinical measurements across space missions. SOMA combines a shared research resource with an international astronaut biobank.",
   "contribution": "Methodology, formal analysis, investigation, and visualization; supervised computational and statistical work.",
   "detail": [
    "SOMA is a collaborative consortium resource. Dr. Meydan shares corresponding authorship. A companion study in the Inspiration4 package lists him among those who led Inspiration4 data acquisition and sharing, and NASA Twins Study data acquisition and sharing. His supervision refers to computational and statistical work in these studies, not to oversight of the whole consortium or biobank."
   ],
   "sources": [
    {
     "claim": "Resource and authorship",
     "title": "Space Omics and Medical Atlas",
     "publisher": "Nature, 2024",
     "url": "https://www.nature.com/articles/s41586-024-07639-y",
     "locator": "Author contributions",
     "establishes": "The resource, shared corresponding authorship, and listed contributions (methodology, formal analysis, investigation, visualization, review and editing)."
    },
    {
     "claim": "Data leadership",
     "title": "Wu, Du, Overbey et al., Single-cell analysis identifies conserved features of immune dysfunction in simulated microgravity and spaceflight",
     "publisher": "Nature Communications, 2024",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11166937/",
     "locator": "Author contributions",
     "establishes": "“E.O., C.M., J.K., and C.E.M. led I4 data acquisition and sharing. C.M., C.E.M., F.G-B., and A.B. led Twins study data acquisition and sharing.”"
    },
    {
     "claim": "Resource access",
     "title": "SOMA",
     "publisher": "Weill Cornell Medicine",
     "url": "https://soma.weill.cornell.edu/",
     "locator": "",
     "establishes": "Portal landing page and browsers."
    },
    {
     "claim": "Code and data",
     "title": "SOMA dataset and code index",
     "publisher": "Nature collection",
     "url": "https://www.nature.com/collections/ebdbcahdgc/data-code",
     "locator": "",
     "establishes": "Canonical index of SOMA datasets and code."
    }
   ],
   "evidenceScope": "The paper documents the resource, the shared corresponding authorship, and the listed contributions. A companion Inspiration4 study documents his co-leadership of the mission’s data acquisition and sharing.",
   "summaryUrl": "https://www.cemmeydan.com/#spaceflight",
   "detailsUrl": "https://www.cemmeydan.com/evidence/#soma",
   "lastReviewed": "2026-10-31",
   "resources": [
    {
     "type": "Portal",
     "name": "SOMA resource",
     "url": "https://soma.weill.cornell.edu/"
    },
    {
     "type": "Portal",
     "name": "SOMA Browser",
     "url": "https://soma.weill.cornell.edu/apps/SOMA_Browser/"
    },
    {
     "type": "Portal",
     "name": "PBMC Multiome Browser",
     "url": "https://soma.weill.cornell.edu/apps/I4_Multiome/"
    },
    {
     "type": "Portal",
     "name": "Inspiration4 Microbiome Browser",
     "url": "https://soma.weill.cornell.edu/apps/I4_Microbiome/"
    },
    {
     "type": "Code",
     "name": "Inspiration4 study code",
     "url": "https://github.com/eliah-o/inspiration4-omics"
    },
    {
     "type": "Index",
     "name": "SOMA dataset and code index (Nature)",
     "url": "https://www.nature.com/collections/ebdbcahdgc/data-code"
    },
    {
     "type": "Public data",
     "name": "OSD-574 · skin biopsies",
     "url": "https://osdr.nasa.gov/bio/repo/data/studies/OSD-574/"
    },
    {
     "type": "Public data",
     "name": "OSD-630 · stool",
     "url": "https://osdr.nasa.gov/bio/repo/data/studies/OSD-630/"
    },
    {
     "type": "Public data",
     "name": "OSD-572 · crew swabs",
     "url": "https://osdr.nasa.gov/bio/repo/data/studies/OSD-572/"
    },
    {
     "type": "Public data",
     "name": "OSD-573 · capsule swabs",
     "url": "https://osdr.nasa.gov/bio/repo/data/studies/OSD-573/"
    },
    {
     "type": "Public data",
     "name": "OSD-575 · blood serum",
     "url": "https://osdr.nasa.gov/bio/repo/data/studies/OSD-575/"
    },
    {
     "type": "Public data",
     "name": "OSD-656 · urine",
     "url": "https://osdr.nasa.gov/bio/repo/data/studies/OSD-656/"
    },
    {
     "type": "Biospecimen request",
     "name": "CAMbank: Cornell Aerospace Medicine Biobank",
     "url": "https://cambank.weill.cornell.edu/"
    }
   ]
  },
  {
   "id": "nasa-twins",
   "title": "NASA Twins Study",
   "venue": "Science",
   "year": "2019",
   "paperDoi": "10.1126/science.aau8650",
   "studyGroup": "spaceflight",
   "personId": "https://www.cemmeydan.com/#cem-meydan",
   "personName": "Cem Meydan",
   "authorship": [
    "First author"
   ],
   "personRoles": [
    "co-first author",
    "transcriptomic methods",
    "integrative analysis",
    "formal analysis",
    "manuscript development",
    "co-led Twins data acquisition and sharing"
   ],
   "finding": "The NASA Twins Study compared a year-long spaceflight with an identical-twin ground control. It integrated molecular and physiological measurements across the mission.",
   "contribution": "Transcriptomic and integrative-analysis methods, formal analysis, and manuscript development.",
   "detail": [
    "The NASA Twins Study was a multi-institution NASA program. Dr. Meydan’s role was within that collaboration. Human research data are available by request through the NASA Life Sciences Portal. They are not an open download."
   ],
   "sources": [
    {
     "claim": "Study and authorship",
     "title": "Garrett-Bakelman et al., The NASA Twins Study",
     "publisher": "Science, 2019",
     "url": "https://doi.org/10.1126/science.aau8650",
     "locator": "",
     "establishes": "The study and its authorship."
    },
    {
     "claim": "Author manuscript",
     "title": "NASA Twins Study (PMC)",
     "publisher": "PubMed Central",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7580864/",
     "locator": "Author contributions",
     "establishes": "Open author manuscript and contribution list."
    },
    {
     "claim": "Data leadership",
     "title": "Wu, Du, Overbey et al., Single-cell analysis identifies conserved features of immune dysfunction in simulated microgravity and spaceflight",
     "publisher": "Nature Communications, 2024",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC11166937/",
     "locator": "Author contributions",
     "establishes": "“C.M., C.E.M., F.G-B., and A.B. led Twins study data acquisition and sharing.”"
    },
    {
     "claim": "Data access",
     "title": "Data request FAQ",
     "publisher": "NASA Life Sciences Portal",
     "url": "https://nlsp.nasa.gov/Request/dataRequestFAQ",
     "locator": "",
     "establishes": "Request route for controlled human data."
    }
   ],
   "evidenceScope": "The paper and its author manuscript document the study, the shared first authorship, and the listed contributions. A later study documents his co-leadership of the Twins data acquisition and sharing.",
   "summaryUrl": "https://www.cemmeydan.com/#spaceflight",
   "detailsUrl": "https://www.cemmeydan.com/evidence/#nasa-twins",
   "lastReviewed": "2026-10-31",
   "resources": [
    {
     "type": "Controlled data (request access)",
     "name": "NASA Life Sciences Portal data requests",
     "url": "https://nlsp.nasa.gov/Request/dataRequestFAQ"
    },
    {
     "type": "Paper",
     "name": "Author manuscript (PMC)",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7580864/"
    }
   ]
  },
  {
   "id": "spaceflight-mitochondria",
   "title": "Mitochondrial stress during spaceflight",
   "venue": "Cell",
   "year": "2020",
   "paperDoi": "10.1016/j.cell.2020.11.002",
   "studyGroup": "spaceflight",
   "personId": "https://www.cemmeydan.com/#cem-meydan",
   "personName": "Cem Meydan",
   "authorship": [
    "First author"
   ],
   "personRoles": [
    "co-first author",
    "DNA methylation analysis"
   ],
   "finding": "This study integrated astronaut profiles with experimental-model data. The findings identified mitochondrial stress as a central biological response to spaceflight.",
   "contribution": "Analyzed DNA methylation data.",
   "detail": [
    "WGCNA code is provided in the article’s Methods S1 supplement. Study metabolomics are at OSD-343 (formerly GLDS-343). The article’s Key Resources Table lists the additional GeneLab datasets it reuses."
   ],
   "sources": [
    {
     "claim": "Study and authorship",
     "title": "da Silveira et al., Comprehensive Multi-Omics Analysis Reveals Mitochondrial Stress as a Central Biological Hub for Spaceflight Impact",
     "publisher": "Cell, 2020",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7870178/",
     "locator": "Author contributions",
     "establishes": "The study, shared first authorship, and listed contributions."
    },
    {
     "claim": "Data",
     "title": "OSD-343",
     "publisher": "NASA Open Science Data Repository",
     "url": "https://osdr.nasa.gov/bio/repo/data/studies/OSD-343",
     "locator": "",
     "establishes": "Study metabolomics."
    }
   ],
   "evidenceScope": "The paper documents the study, the shared first authorship, and the listed contributions.",
   "summaryUrl": "https://www.cemmeydan.com/#spaceflight",
   "detailsUrl": "https://www.cemmeydan.com/evidence/#spaceflight-mitochondria",
   "lastReviewed": "2026-10-31",
   "resources": [
    {
     "type": "Public data",
     "name": "OSD-343 · study metabolomics",
     "url": "https://osdr.nasa.gov/bio/repo/data/studies/OSD-343"
    },
    {
     "type": "Paper",
     "name": "Open article and supplements (PMC)",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7870178/"
    }
   ]
  },
  {
   "id": "enasidenib",
   "title": "IDH2 inhibition: epigenomic evidence for a targeted leukemia therapy",
   "venue": "Cancer Discovery",
   "year": "2017",
   "paperDoi": "10.1158/2159-8290.CD-16-1049",
   "studyGroup": "enasidenib-mechanism",
   "personId": "https://www.cemmeydan.com/#cem-meydan",
   "personName": "Cem Meydan",
   "authorship": [
    "First author"
   ],
   "personRoles": [
    "co-first author",
    "methodology",
    "computational analysis and data interpretation",
    "manuscript writing"
   ],
   "finding": "Preclinical studies linked mutant IDH2 inhibition to reduced abnormal DNA methylation and restored differentiation in leukemia models. The first enasidenib clinical report cited the 2014 AG-221 findings. A clinical-mechanism study cited both the 2014 and 2017 work.",
   "contribution": "Methodology development, computational analysis and interpretation of epigenomic data, and manuscript writing.",
   "detail": [
    "The initial enasidenib clinical report cites the 2014 AG-221 findings of Shih, Shank, Meydan and colleagues. The clinical-mechanism study also cites the 2017 Cancer Discovery paper by Shih, Meydan and colleagues. The 2017 paper’s Authors’ Contributions list C. Meydan under development of methodology; analysis and interpretation of data (statistical and computational analysis); writing, review, and revision of the manuscript; and administrative, technical, or material support (organizing data, constructing databases)."
   ],
   "sources": [
    {
     "claim": "Mechanistic and epigenomic findings",
     "title": "Shih, Meydan et al., combination targeted therapy in IDH2- and TET2-mutant AML",
     "publisher": "Cancer Discovery, 2017",
     "url": "https://aacrjournals.org/cancerdiscovery/article/7/5/494/6297/Combination-Targeted-Therapy-to-Disrupt-Aberrant",
     "locator": "Authors’ Contributions",
     "establishes": "Preclinical findings, shared first authorship, and the contribution record: methodology; analysis and interpretation of data; writing, review, and revision; administrative, technical, or material support."
    },
    {
     "claim": "Author manuscript",
     "title": "Shih, Meydan et al. (PMC)",
     "publisher": "PubMed Central",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5413413/",
     "locator": "",
     "establishes": "Open author manuscript of the 2017 paper."
    },
    {
     "claim": "Connection to the initial clinical report",
     "title": "Stein et al., Enasidenib in mutant IDH2 relapsed or refractory AML",
     "publisher": "Blood, 2017",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5572791/",
     "locator": "Reference 19",
     "establishes": "Cites the 2014 AG-221 findings of Shih, Shank, Meydan and colleagues."
    },
    {
     "claim": "Connection to clinical-mechanism work",
     "title": "Amatangelo et al., Enasidenib induces AML differentiation",
     "publisher": "Blood, 2017",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC5553578/",
     "locator": "References 15 and 17",
     "establishes": "Cites the earlier AG-221 work and the 2017 mechanistic paper."
    },
    {
     "claim": "Approval of enasidenib",
     "title": "FDA approves new targeted treatment for relapsed or refractory AML",
     "publisher": "U.S. FDA, August 1, 2017",
     "url": "https://www.fda.gov/news-events/press-announcements/fda-approves-new-targeted-treatment-relapsed-or-refractory-acute-myeloid-leukemia",
     "locator": "",
     "establishes": "The drug’s approval milestone. Not a record of individual contributions."
    }
   ],
   "evidenceScope": "These records document the scientific and clinical-publication connection.",
   "summaryUrl": "https://www.cemmeydan.com/#enasidenib-mechanism",
   "detailsUrl": "https://www.cemmeydan.com/evidence/#enasidenib",
   "lastReviewed": "2026-10-31",
   "roleScope": "2017 Cancer Discovery paper",
   "milestone": "Drug milestone: FDA approval · 2017",
   "clinicalPaperDois": [
    "10.1182/blood-2017-04-779405",
    "10.1182/blood-2017-04-779447"
   ],
   "regulatoryContext": [
    {
     "title": "FDA approval package · NDA 209606",
     "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000TOC.html",
     "note": "Approval documents for enasidenib."
    },
    {
     "title": "FDA correspondence · PDF page 195",
     "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000AdminCorres.pdf#page=195",
     "note": "An FDA request for an in-vitro DNA-hypermethylation reversal study."
    },
    {
     "title": "FDA multidisciplinary review",
     "url": "https://www.accessdata.fda.gov/drugsatfda_docs/nda/2017/209606Orig1s000MultidisciplineR.pdf",
     "note": "The agency’s review of the application."
    }
   ]
  },
  {
   "id": "rt-lamp",
   "title": "Rapid RT-LAMP testing and SARS-CoV-2 tracking in New York",
   "venue": "Nature Communications",
   "year": "2021",
   "paperDoi": "10.1038/s41467-021-21361-7",
   "studyGroup": "public-health",
   "personId": "https://www.cemmeydan.com/#cem-meydan",
   "personName": "Cem Meydan",
   "authorship": [
    "First author"
   ],
   "personRoles": [
    "co-first author",
    "assay protocol and primer design",
    "statistical validation",
    "genetic analysis"
   ],
   "finding": "The study combined RT-LAMP testing with viral sequencing, host-response profiling, and spatial measurements across clinical specimens from New York’s first wave. The sequencing tracked the lineage that dominated New York’s early outbreak. The validation results contributed to the evidence supporting Color’s FDA emergency authorization in May 2020.",
   "contribution": "Helped design the RT-LAMP protocol and primers, and validated the test statistically against RT-PCR, shotgun sequencing, and clinical health records; performed genetic and statistical analyses.",
   "detail": [
    "The study combined viral sequencing, host gene-expression analysis, and rapid testing across clinical samples from New York. The RT-LAMP validation used RT-PCR as a comparator. The collaboration included Weill Cornell Medicine, Color, and New England Biolabs.",
    "The broader study profiled 669 unique patients. The RT-LAMP validation used a separate set of 201 samples.",
    "The emergency authorization is a historical milestone for the assay."
   ],
   "sources": [
    {
     "claim": "Study, assay and authorship",
     "title": "Butler, Mozsary, Meydan et al., Shotgun transcriptome, spatial omics, and isothermal profiling of SARS-CoV-2",
     "publisher": "Nature Communications, 2021",
     "url": "https://www.nature.com/articles/s41467-021-21361-7",
     "locator": "",
     "establishes": "The study, the RT-LAMP validation, and shared first authorship."
    },
    {
     "claim": "Assay collaboration and authorization",
     "title": "Researchers create rapid diagnostic tests and multi-omics analytics platforms for SARS-CoV-2",
     "publisher": "Weill Cornell Medicine, March 2021",
     "url": "https://news.weill.cornell.edu/news/2021/03/researchers-create-rapid-diagnostic-tests-and-multi-omics-analytics-platforms-for-sars",
     "locator": "",
     "establishes": "Institutional account of the collaboration and Color’s authorization."
    },
    {
     "claim": "Press account of his role",
     "title": "New coronavirus test gives results in 30 minutes (in Turkish)",
     "publisher": "The Independent (Turkish edition), 2020",
     "url": "https://www.indyturk.com/node/197341/sa%C4%9Flik/yeni-koronavir%C3%BCs-testi-30-dakikada-sonucu-veriyor-g%C3%BCnde-1-milyondan-fazla-test",
     "locator": "",
     "establishes": "Names Dr. Meydan of Weill Cornell Medicine as working on the LAMP test. An archived copy is in the media section."
    },
    {
     "claim": "Emergency authorization",
     "title": "Color authorization letter",
     "publisher": "U.S. FDA, May 2020",
     "url": "https://www.fda.gov/media/138248/download",
     "locator": "",
     "establishes": "The assay’s historical emergency authorization."
    },
    {
     "claim": "Data",
     "title": "dbGaP phs002258.v1.p1",
     "publisher": "NCBI dbGaP",
     "url": "https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002258.v1.p1",
     "locator": "",
     "establishes": "Controlled-access sequencing and specimen metadata. The record points to a newer version."
    }
   ],
   "evidenceScope": "The paper and the institutional account document the assay, the sequencing, and the collaboration, and the paper records his shared first authorship. Its contribution statement credits other authors with the wet-lab LAMP experiments. A 2020 Independent Türkçe report quotes him as working on the LAMP test.",
   "summaryUrl": "https://www.cemmeydan.com/#public-health",
   "detailsUrl": "https://www.cemmeydan.com/evidence/#rt-lamp",
   "lastReviewed": "2026-10-31",
   "resources": [
    {
     "type": "Portal",
     "name": "COVID Genes (host and viral expression)",
     "url": "https://covidgenes.weill.cornell.edu/"
    },
    {
     "type": "Controlled data (request access)",
     "name": "dbGaP phs002258.v1.p1 (paper-cited version)",
     "url": "https://www.ncbi.nlm.nih.gov/projects/gap/cgi-bin/study.cgi?study_id=phs002258.v1.p1"
    },
    {
     "type": "Public data",
     "name": "Viral genomes MW493710–MW493863 (GenBank)",
     "url": "https://www.ncbi.nlm.nih.gov/nuccore/MW493710"
    }
   ]
  },
  {
   "id": "covid-tissue",
   "title": "System-wide tissue damage in COVID-19",
   "venue": "Cell Reports Medicine",
   "year": "2022",
   "paperDoi": "10.1016/j.xcrm.2022.100522",
   "studyGroup": "public-health",
   "personId": "https://www.cemmeydan.com/#cem-meydan",
   "personName": "Cem Meydan",
   "authorship": [
    "Corresponding author"
   ],
   "personRoles": [
    "co-corresponding author",
    "RNA-seq bioinformatics",
    "statistical investigation"
   ],
   "finding": "Autopsy and nasopharyngeal profiling showed that COVID-19 disrupts transcriptional programs and tissue identity across many organs. In the lung, these changes tracked viral load and disease stage.",
   "contribution": "Performed RNA-seq bioinformatics analyses and statistical investigations.",
   "detail": [],
   "sources": [
    {
     "claim": "Findings, authorship and contribution",
     "title": "Park, Foox, Hether et al., System-wide transcriptome damage and tissue identity loss in COVID-19 patients",
     "publisher": "Cell Reports Medicine, 2022",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8784611/",
     "locator": "Author contributions",
     "establishes": "Corresponding authorship and RNA-seq bioinformatics and statistical analyses."
    }
   ],
   "evidenceScope": "The paper documents the findings, the shared corresponding authorship, and the listed contributions.",
   "summaryUrl": "https://www.cemmeydan.com/#public-health",
   "detailsUrl": "https://www.cemmeydan.com/evidence/#covid-tissue",
   "lastReviewed": "2026-10-31",
   "resources": [
    {
     "type": "Portal",
     "name": "COVID Genes (autopsy and swab expression)",
     "url": "https://covidgenes.weill.cornell.edu/"
    }
   ]
  },
  {
   "id": "covid-host",
   "title": "Host response and severe COVID-19 outcomes",
   "venue": "Nature Medicine",
   "year": "2020",
   "paperDoi": "10.1038/s41591-020-1021-2",
   "studyGroup": "public-health",
   "personId": "https://www.cemmeydan.com/#cem-meydan",
   "personName": "Cem Meydan",
   "authorship": [
    "Coauthor"
   ],
   "personRoles": [
    "coauthor",
    "data collection and organization",
    "data analysis",
    "spatial transcriptomics"
   ],
   "finding": "Health records and nasal-swab transcriptomes linked complement and coagulation activation to ventilation and death (Nature Medicine). Spatial profiling of autopsy lungs mapped infected alveolar cells and the inflammation and repair that followed (Nature).",
   "contribution": "Collected and organized data and contributed to data analysis (Nature Medicine). Contributed to the digital spatial transcriptomics (Nature).",
   "detail": [],
   "sources": [
    {
     "claim": "Complement and coagulation findings; contribution",
     "title": "Ramlall, Thangaraj, Meydan et al., Immune complement and coagulation dysfunction in adverse outcomes of SARS-CoV-2 infection",
     "publisher": "Nature Medicine, 2020",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7809634/",
     "locator": "Author contributions",
     "establishes": "Data collection and organization, and data analysis."
    },
    {
     "claim": "Lung pathology findings; contribution",
     "title": "Rendeiro, Ravichandran, Bram et al., The spatial landscape of lung pathology during COVID-19 progression",
     "publisher": "Nature, 2021",
     "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC8204801/",
     "locator": "Author contributions",
     "establishes": "Contributions to the digital spatial transcriptomics."
    }
   ],
   "evidenceScope": "Each paper’s author-contribution statement lists these roles.",
   "summaryUrl": "https://www.cemmeydan.com/#public-health",
   "detailsUrl": "https://www.cemmeydan.com/evidence/#covid-host",
   "lastReviewed": "2026-10-31",
   "dois": [
    "10.1038/s41591-020-1021-2",
    "10.1038/s41586-021-03475-6"
   ]
  }
 ],
 "ventures": {
  "personId": "https://www.cemmeydan.com/#cem-meydan",
  "context": "Ventures: external work, separate from the Meydan Lab",
  "summary": "Dr. Meydan joined Onegevity as a founding employee and built the GutBio product and analytical platform. He continued research and microbiome product leadership at Thorne HealthTech through its IPO and subsequent acquisition. He is also a co-founder of ARQ.",
  "ventures": [
   {
    "id": "onegevity",
    "name": "Onegevity / Thorne HealthTech",
    "role": "Founding employee · GutBio product and research leadership",
    "text": "Dr. Meydan joined Onegevity as a founding employee and built the GutBio product and analytical platform from the ground up. He continued to lead research and microbiome product development at Thorne HealthTech after the merger. His work spanned the company’s 2021 IPO and its 2023 acquisition by L Catterton. GutBio supported commercial microbiome testing in the United States and Japan.",
    "milestones": [
     {
      "year": "2021",
      "event": "Onegevity and Thorne merge and form Thorne HealthTech."
     },
     {
      "year": "2021",
      "event": "Thorne HealthTech completes its IPO on Nasdaq."
     },
     {
      "year": "2023",
      "event": "L Catterton acquires Thorne HealthTech."
     }
    ],
    "sources": [
     {
      "title": "Metagenome-guided intervention study",
      "publisher": "Precision Clinical Medicine, 2020",
      "url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC7327130/",
      "establishes": "The study, Dr. Meydan’s shared first authorship, and his author affiliation: Onegevity Health, New York."
     },
     {
      "title": "Wipe-based stool collection and preservation kit",
      "publisher": "Frontiers in Immunology, 2022",
      "url": "https://doi.org/10.3389/fimmu.2022.889702",
      "establishes": "Dr. Meydan’s author affiliation is Thorne HealthTech. The same affiliation appears on the high-altitude case study (Heliyon, 2024) and the PCOS study (Precision Clinical Medicine, 2025), and Thorne Research on the breast cancer survivors atlas (Metabolites, 2024); all are listed under the research above."
     },
     {
      "title": "Nathan Price, Thorne chief science officer: “Microbiome: Mastering the Market”",
      "publisher": "Naturally Informed, June 2024 (slides)",
      "url": "https://naturallyinformed.net/wp-content/uploads/2024/06/Nathan-Price-Microbiome-Mastering-the-Market-2024-PDF-compressed.pdf#page=9",
      "establishes": "The acknowledgements credit “Cem Meydan, Ph.D., Scientific Researcher, Thorne HealthTech”. A Thorne Gut Health Test slide presents the IBS intervention results and cites Meydan C, et al., Precis Clin Med 2020."
     },
     {
      "title": "Nathan Price, Thorne chief science officer, conference slides",
      "publisher": "Naturally Informed, May 2023 (slides)",
      "url": "https://naturallyinformed.net/wp-content/uploads/2023/05/Nathan-Price-Slides-compressed.pdf#page=8",
      "establishes": "The same acknowledgement and IBS-study slide."
     },
     {
      "title": "Nathan Price: “Future of the Microbiome”",
      "publisher": "Future of the Microbiome, December 2022 (slides)",
      "url": "https://futureofmicrobiome.com/wp-content/uploads/2022/12/Price-Future-of-the-microbiome.pdf#page=7",
      "establishes": "The same acknowledgement of Dr. Meydan at Thorne HealthTech."
     },
     {
      "title": "Loukia Lili, former Thorne HealthTech senior director of bioinformatics: high-altitude tent study write-up",
      "publisher": "Personal blog, May 2022",
      "url": "https://loukialili.blogspot.com/2022/05/performance-and-metabolic-benefits.html",
      "establishes": "Lists “Cem Meydan, PhD – Principal bioinformatician, Thorne HealthTech Inc., study co-lead”. The study was later published in Heliyon (2024)."
     },
     {
      "title": "Thorne HealthTech IPO registration statement",
      "publisher": "SEC, September 2021",
      "url": "https://www.sec.gov/Archives/edgar/data/1844280/000119312521279185/d162335ds1a.htm",
      "establishes": "Business section, “Gut Health Test” (prospectus p. 113): describes the 88-participant IBS intervention study and cites “Meydan C, et al. Improved gastrointestinal health for irritable bowel syndrome with metagenome-guided interventions. Precis Clin Med. 2020”."
     },
     {
      "title": "Space Omics and Medical Atlas, competing interests",
      "publisher": "Nature, 2024",
      "url": "https://www.nature.com/articles/s41586-024-07639-y",
      "establishes": "The competing-interests statement records Dr. Meydan’s compensation by Thorne HealthTech."
     },
     {
      "title": "Thorne merges with Onegevity",
      "publisher": "Thorne, 2021",
      "url": "https://www.thorne.com/press-releases/thorne-merges-with-onegevity-announces-new-parent-company-thorne-healthtech",
      "establishes": "The merger and the new parent company."
     },
     {
      "title": "L Catterton completes acquisition of Thorne HealthTech",
      "publisher": "Thorne, 2023",
      "url": "https://www.thorne.com/press-releases/l-catterton-completes-acquisition-of-thorne-healthtech-inc",
      "establishes": "The acquisition."
     },
     {
      "title": "Japan testing agreement",
      "publisher": "SEC quarterly filing, June 2023",
      "url": "https://www.sec.gov/Archives/edgar/data/1844280/000095017023040161/thrn-20230630.htm",
      "establishes": "Commercial testing in Japan."
     },
     {
      "title": "Kirin MicroBio Me launch",
      "publisher": "Kirin Holdings, July 2023",
      "url": "https://www.kirinholdings.com/jp/newsroom/release/2023/0718_01.html",
      "establishes": "The Japanese consumer launch."
     },
     {
      "title": "Thorne 2022 annual report",
      "publisher": "SEC, 2023",
      "url": "https://www.sec.gov/Archives/edgar/data/1844280/000095017023011358/thrn-20221231.htm",
      "establishes": "IPO history."
     }
    ],
    "evidenceScope": "Author affiliations document Dr. Meydan at Onegevity Health (2020) and at Thorne HealthTech and Thorne Research (2022–2025). The IPO registration statement and Thorne’s chief science officer’s conference slides (2023–2024) cite his IBS study as the evidence behind the Gut Health Test, and the officer’s slides (2022–2024), a former colleague’s study write-up, and published competing-interest statements record his Thorne HealthTech role. Corporate filings and announcements document the merger, IPO, acquisition, and Japanese commercialization. Onegevity’s own team pages went offline after the merger, so his founding-employee timing and day-to-day product-build responsibilities are his own account. The companies are separate from the Meydan Lab and Weill Cornell Medicine.",
    "detailsUrl": "https://www.cemmeydan.com/evidence/#onegevity"
   },
   {
    "id": "arq",
    "name": "ARQ",
    "role": "Co-founder",
    "text": "Dr. Meydan is a co-founder of ARQ. The company develops data-driven approaches to human performance.",
    "url": "https://www.onearq.com/",
    "detailsUrl": "https://www.cemmeydan.com/evidence/#arq"
   }
  ]
 },
 "resources": [
  {
   "name": "SOMA",
   "purpose": "Space Omics and Medical Atlas landing page and linked study resources.",
   "years": "2024–",
   "type": "Consortium resource",
   "access": "Open portal",
   "relatedStudy": "soma",
   "url": "https://soma.weill.cornell.edu/"
  },
  {
   "name": "SOMA Browser",
   "purpose": "Browse multiomic data from Inspiration4, Polaris Dawn, Axiom and control participants.",
   "years": "2024–",
   "type": "Interactive portal",
   "access": "Open portal",
   "relatedStudy": "soma",
   "url": "https://soma.weill.cornell.edu/apps/SOMA_Browser/"
  },
  {
   "name": "PBMC Multiome Browser",
   "purpose": "Explore single-cell multiome data from Inspiration4 blood samples.",
   "years": "2024–",
   "type": "Interactive portal",
   "access": "Open portal",
   "relatedStudy": "soma",
   "url": "https://soma.weill.cornell.edu/apps/I4_Multiome/"
  },
  {
   "name": "Inspiration4 Microbiome Browser",
   "purpose": "Explore microbiome data from the Inspiration4 crew and capsule.",
   "years": "2024–",
   "type": "Interactive portal",
   "access": "Open portal",
   "relatedStudy": "soma",
   "url": "https://soma.weill.cornell.edu/apps/I4_Microbiome/"
  },
  {
   "name": "CAMbank",
   "purpose": "Cornell Aerospace Medicine Biobank of spaceflight specimens.",
   "years": "2024–",
   "type": "Biospecimen resource",
   "access": "Sample requests by proposal",
   "relatedStudy": "soma",
   "url": "https://cambank.weill.cornell.edu/"
  },
  {
   "name": "COVID Genes",
   "purpose": "Explore host and viral gene expression in SARS-CoV-2 infection.",
   "years": "2020–",
   "type": "Research portal",
   "access": "Open portal",
   "relatedStudy": "rt-lamp",
   "url": "https://covidgenes.weill.cornell.edu/"
  },
  {
   "name": "MetaSUB Map",
   "purpose": "Urban microbiome sampling and visualization. The portal credits Cem Meydan and David Danko.",
   "years": "2016–",
   "type": "Consortium resource",
   "access": "Open portal",
   "relatedStudy": null,
   "url": "https://metasub.org/map/"
  },
  {
   "name": "StuckOnU 2017",
   "purpose": "Visualization of a 48-hour phone-swabbing experiment. The page credits the website and visualizations to Cem Meydan.",
   "years": "2017",
   "type": "Historical visualization",
   "access": "Open page",
   "relatedStudy": null,
   "url": "https://metasub.org/stuckonu2017/"
  },
  {
   "name": "PathoMap",
   "purpose": "New York City subway microbiome map (2015).",
   "years": "2015",
   "type": "Historical resource",
   "access": "Availability varies",
   "relatedStudy": null,
   "url": "https://pathomap.org/map"
  }
 ]
}